Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Hypoxia and necrosis are fundamental features of glioblastoma (GBM) and their emergence is critical for the rapid biological progression of this fatal tumor; yet, underlying mechanisms are poorly understood. We have suggested that vaso-occlusion following intravascular thrombosis could initiate or propagate hypoxia and necrosis in GBM. Tissue factor (TF), the main cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for TF up-regulation. The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII. Here, we show that overexpression of EGFR or EGFRvIII in human glioma cells causes increased basal TF expression and that stimulation of EGFR by its ligand, EGF, leads to a marked dose-dependent up-regulation of TF. In all cases, increased TF expression led to accelerated plasma coagulation in vitro. EGFR-mediated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and was associated with c-Jun NH(2)-terminal kinase (JNK) and JunD activation. Restoration of PTEN expression in PTEN-deficient GBM cells diminished EGFR-induced TF expression by inhibiting JunD/AP-1 transcriptional activity. PTEN mediated this effect by antagonizing phosphatidylinositol 3-kinase activity, which in turn attenuated both Akt and JNK activities. These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens.

[1]  Michael Karin,et al.  NF-kappaB and cancer-identifying targets and mechanisms. , 2008, Current opinion in genetics & development.

[2]  D. Brat,et al.  RESEARCH ARTICLE: Intravascular Thrombosis in Central Nervous System Malignancies: A Potential Role in Astrocytoma Progression to Glioblastoma , 2007, Brain pathology.

[3]  Zhiwei Hu,et al.  Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. , 2007, Blood.

[4]  Hong Wu,et al.  Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. , 2007, Cancer cell.

[5]  P. Vogt,et al.  A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth , 2007, Oncogene.

[6]  Wei Chen,et al.  Differential regulation and properties of MAPKs , 2007, Oncogene.

[7]  Yuri Kotliarov,et al.  High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. , 2006, Cancer research.

[8]  Erwin G. Van Meir,et al.  Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. , 2006, Cancer research.

[9]  Daniel J Brat,et al.  'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.

[10]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[11]  A. Maity,et al.  EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. , 2006, Cancer research.

[12]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[13]  Dejan Juric,et al.  Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. , 2005, Cancer research.

[14]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[15]  Erwin G. Van Meir,et al.  PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. , 2005, Cancer research.

[16]  S. Shirasawa,et al.  Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. , 2005, Blood.

[17]  Yan Liu,et al.  Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes , 2004, Oncogene.

[18]  P. Carmeliet,et al.  Regulation of angiogenesis by tissue factor cytoplasmic domain signaling , 2004, Nature Medicine.

[19]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[20]  Daniel J Brat,et al.  Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population , 2004, Cancer Research.

[21]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[22]  Mehdi Tnani,et al.  Elevated JNK activation contributes to the pathogenesis of human brain tumors , 2002, Oncogene.

[23]  P. Libby,et al.  Induction of Tissue Factor Expression in Human Endothelial Cells by CD40 Ligand Is Mediated via Activator Protein 1, Nuclear Factor κB, and Egr-1* , 2002, The Journal of Biological Chemistry.

[24]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[25]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[26]  David Baltimore,et al.  Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors , 2002, Science.

[27]  A. Falanga,et al.  Molecular basis for the relationship between thrombosis and cancer. , 2001, Thrombosis research.

[28]  P. Carmeliet,et al.  Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Kyriakis,et al.  Signaling by the Germinal Center Kinase Family of Protein Kinases* , 1999, The Journal of Biological Chemistry.

[30]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[31]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[32]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[33]  J. Kuratsu,et al.  Expression of tissue factor correlates with grade of malignancy in human glioma , 1996, Cancer.

[34]  G. Hair,et al.  In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease , 1996, Nature Medicine.

[35]  S. Tebbutt,et al.  Extrinsic-pathway activation in cancer with high factor Vlla and tissue factor , 1995, The Lancet.

[36]  N. Mackman Regulation of the tissue factor gene , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S B Green,et al.  Patient age, histologic features, and length of survival in patients with glioblastoma multiforme , 1987, Cancer.

[40]  M. Karin,et al.  NF- κ B and Cancer — Identifying Targets and Mechanisms , 2008 .